Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer

被引:1
|
作者
Nisman, B [1 ]
Amir, G
Lafair, J
Heching, N
Lyass, O
Peretz, T
Barak, V
机构
[1] Hadassah Univ Hosp, Dept Oncol, Immunol Lab Tumor Diag, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Pulm Unit, IL-91120 Jerusalem, Israel
关键词
TPS; CYFRA; 21-1; CEA; NSCLC; adenocarcinoma; squamous-cell carcinoma; large-cell carcinoma; prognosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic value of the tumor markers CYFRA 21-1, tissue polypeptide specific antigen (TPS) and carcinoembryonic antigen (CEA) was investigated in three histologic subtypes of non-small cell lung cancer. Pretreatment saran marker levels were measured in 38 patients with adenocarcinoma (AC), in 43 patients with squamous cell carcinoma (SQC) and in 35 patients with large cell carcinoma (LCC). Univariate analysis in AC showed significant lower survival of patients with elevated levels of TPS, CYFRA 21-1 and CEA. In LCC, elevated levels of TPS and CEA were found to predict lower survival, while in SQC - only TPS was a predictor: A multivariate analysis of survival identified CEA (Relative Risk-5.5; p=0.004), CYFRA 21-1 (RR-3.4; p=0.008) and TPS (RR-3.0; p=0.02) as independent prognostic factors in AC. In sect only TPS (RR-2.3; p=0.03) was such a factor whereas in LC - none of the markers studied retained statistical significance. Thereafter; the combinations of the two strongest prognostic factors in the AC group - CEA and CYFRA 21-1 were explored to divide this group into subsets with different prognosis. In cases where both markers were positive, the relative risk of death was 10.5 times higher as compared to cases where both markers were negative (p=0.002).
引用
收藏
页码:3549 / 3552
页数:4
相关论文
共 50 条
  • [31] Evaluation of Cyfra 21-1: A Potential Tumor Marker for Non-Small Cell Lung Carcinomas
    D. Karnak
    G. Ulubay
    O. Kayacan
    S. Beder
    E. İbis
    G. Oflaz
    Lung, 2001, 179 : 57 - 65
  • [32] Evaluation of Cyfra 21-1: A potential tumor marker for non-small cell lung carcinomas
    Karnak, D
    Ulubay, G
    Kayacan, O
    Beder, S
    Ibis, E
    Oflaz, G
    LUNG, 2001, 179 (01) : 57 - 65
  • [33] THE DIAGNOSTIC AND PROGNOSTIC VALUE OF THE MARKERS SCC, TPS AND CYFRA 21-1 IN HEAD AND NECK CANCER PATIENTS
    Barak, Vivian
    Wigoda, M.
    Rachmut, K.
    Nisman, B.
    Peretz, T.
    Elidan, J.
    Gross, M.
    TUMOR BIOLOGY, 2010, 31 : S94 - S94
  • [34] Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients
    Kagawa, Yusuke
    Sone, Kazuki
    Oguri, Tetsuya
    Horiuchi, Minoru
    Fukuda, Satoshi
    Uemura, Takehiro
    Takakuwa, Osamu
    Maeno, Ken
    Fukumitsu, Kennsuke
    Kanemitsu, Yoshihiro
    Tajiri, Tomoko
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Ito, Yutaka
    Niimi, Akio
    RESPIRATORY INVESTIGATION, 2022, 60 (03) : 393 - 399
  • [35] Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS
    Pujol, JL
    Grenier, J
    Parrat, E
    Lehmann, M
    Lafontaine, T
    Quantin, X
    Michel, FB
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) : 725 - 733
  • [36] CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy
    Ebert, W
    Muley, T
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2669 - 2672
  • [37] Serum CYFRA 21-1 as a prognostic marker in lung cancer
    Pujol, JL
    Grenier, J
    Pujol, H
    Michel, EB
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1256 - 1256
  • [38] Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer
    Nakao, Makoto
    Kinoshita, Ryosuke
    Kuriyama, Mamiko
    Kiyotoshi, Hiroko
    Sugihara, Masahiro
    Takeda, Norihisa
    Ohtakara, Kazuhiro
    Muramatsu, Hideki
    ANTICANCER RESEARCH, 2024, 44 (02) : 845 - 851
  • [39] Serum CYFRA 21-1 as a biomarker of pemetrexed plus cisplatin treatment in nonsquamous non-small cell lung cancer
    Sakatani, Toshio
    Ohyanagi, Fumiyoshi
    Tanimoto, Azusa
    Kawano, Yuko
    Saito, Ryota
    Kaburaki, Kyohei
    Yanagitani, Noriko
    Kudo, Keita
    Horiike, Atsushi
    Hagiwara, Sachiko
    Horai, Takeshi
    Nishio, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
    Sone, Kazuki
    Oguri, Tetsuya
    Nakao, Makoto
    Kagawa, Yusuke
    Kurowaka, Ryota
    Furuta, Hiromi
    Fukuda, Satoshi
    Uemura, Takehiro
    Takakuwa, Osamu
    Kanemitsu, Yoshihiro
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Sato, Hidefumi
    Muramatsu, Hideki
    Niimi, Akio
    ANTICANCER RESEARCH, 2017, 37 (02) : 935 - 939